semaglutide cardiovascular outcomes trial (CVOT) Timeline of cardiovascular outcome trials

You can always add more but you cant take it away

DMSO, the vehicle, was used for the no-drug conditions

Stability in medication access removes a major barrier to long-term adherence, helping patients avoid the rebound cycle entirely

More recently, the approval of the first oral GLP-1 analog, semaglutide (Rybelsus), for type 2 diabetes represents a major step forward in addressing one of the key challenges in this field: patient compliance associated with subcutaneous injections

Effects of hemispheric side of injury, age at injury, and presence of seizure disorder on functional ear and hand asymmetries in hemiplegic children